2 High-Flying Dividend Stocks to Buy and Hold for a Decade

Merck and AbbVie have outperformed the S&P 500 year to date, gaining 39% and 24%, respectively, versus about 12% for the index. Merck’s Q2 revenue rose 5% to $16.6B, while AbbVie’s increased 10.2% to nearly $17B and adjusted EPS climbed 22.9% to $3.65. The article highlights Merck’s products and pipeline as potential offsets to Keytruda’s expected 2028 patent loss, and AbbVie’s growth drivers, pipeline and patent protection extending into the 2030s; both companies also have established dividend-growth records.

Analysis

The key divergence is duration of earnings visibility, not simply current growth: AbbVie’s stated U.S. exclusivity runway gives it more time to fund succession, while Merck’s Keytruda exposure makes execution around the 2028 cliff unusually consequential. Merck’s subcutaneous formulation could defend convenience and retain patients, but it does not by itself establish durable protection from biosimilar substitution or preserve current economics; payer access, conversion rates, and formulation-specific IP are the critical checks. The Moderna cancer-vaccine readthrough is positive for both partners, but trial efficacy is not yet commercial value: approval, label breadth, manufacturing, and the partners’ economics remain unresolved.

Near term, strong reported growth can support sentiment, but the cited share gains raise the risk that good news is already reflected. Over 1–3 months, watch guidance, launch uptake and clinical/regulatory updates. Over 6–18 months, the test is whether Merck’s newer products scale enough to offset eventual Keytruda erosion and whether AbbVie broadens growth beyond its two lead immunology drugs. The contrarian risk is treating patent dates as a complete forecast: competition, access and pipeline delays can change the earnings path well before exclusivity expires.

Key Decisions for Investors

• Do not chase the recent rally on this evidence alone. Before adding MRK, verify Keytruda Qlex conversion, formulation-specific patent protection, payer coverage and management’s quantified post-exclusivity plan; weak conversion or deteriorating access would falsify the retention thesis.
• Prefer ABBV over MRK in a valuation-aware relative-value screen, rather than an unconditional outright long: AbbVie’s longer stated U.S. runway offers greater earnings visibility, but entry should depend on current valuation and expectations. Reassess if Skyrizi/Rinvoq growth materially decelerates or pipeline launches fail to advance.
• For a hedged expression, consider a modest long ABBV / short MRK pair only if valuation and borrow checks support it; size to limit exposure to company-specific trial and regulatory shocks. The thesis is relative patent-cycle risk, not a forecast that Merck’s products or pipeline will fail.
• Treat MRNA as a catalyst watch, not a trade based solely on Merck’s partner program. Confirm regulatory milestones, label scope, commercial economics and manufacturing readiness; a delay or narrower-than-expected indication would weaken the readthrough.